Rifalazil Retains Activity Against Rifampin-resistant Mutants of Chlamydia pneumoniae

[1]  D. Rothstein,et al.  Efficacy of Benzoxazinorifamycins in a Mouse Model of Chlamydia pneumoniae Lung Infection , 2008, Antimicrobial Agents and Chemotherapy.

[2]  D. Rothstein,et al.  Rifalazil and Other Benzoxazinorifamycins in the Treatment of Chlamydia‐Based Persistent Infections , 2007, Archiv der Pharmazie.

[3]  W. Stamm,et al.  A Randomized, Double-Blind Study Comparing Single-Dose Rifalazil With Single-Dose Azithromycin for the Empirical Treatment of Nongonococcal Urethritis in Men , 2007, Sexually transmitted diseases.

[4]  S. Ouellette,et al.  Global transcriptional upregulation in the absence of increased translation in Chlamydia during IFNγ‐mediated host cell tryptophan starvation , 2006, Molecular microbiology.

[5]  D. Rothstein,et al.  Development potential of rifalazil and other benzoxazinorifamycins , 2006, Expert opinion on investigational drugs.

[6]  D. Rothstein,et al.  Activity of Novel Benzoxazinorifamycins against Rifamycin-Resistant Streptococcus pyogenes , 2006, Antimicrobial Agents and Chemotherapy.

[7]  M. Osburne,et al.  In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus , 2006, Antimicrobial Agents and Chemotherapy.

[8]  D. Rothstein,et al.  Rifalazil Pretreatment of Mammalian Cell Cultures Prevents Subsequent Chlamydia Infection , 2006, Antimicrobial Agents and Chemotherapy.

[9]  D. Rothstein,et al.  Activities of Rifamycin Derivatives against Wild-Type and rpoB Mutants of Chlamydia trachomatis , 2005, Antimicrobial Agents and Chemotherapy.

[10]  S. Kohlhoff,et al.  Emergence of Resistance to Rifampin and Rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis , 2005, Antimicrobial Agents and Chemotherapy.

[11]  E. Denamur,et al.  Rifampin-Resistant RNA Polymerase Mutants of Chlamydia trachomatis Remain Susceptible to the Ansamycin Rifalazil , 2005, Antimicrobial Agents and Chemotherapy.

[12]  M. Hammerschlag,et al.  In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae , 2003, Antimicrobial Agents and Chemotherapy.

[13]  W. Stamm,et al.  Methodologies and Cell Lines Used for Antimicrobial Susceptibility Testing of Chlamydia spp , 2003, Antimicrobial Agents and Chemotherapy.

[14]  D. Rothstein,et al.  Development potential of rifalazil , 2003, Expert opinion on investigational drugs.

[15]  G. Bai,et al.  Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  John L. Johnson,et al.  Safety and Bactericidal Activity of Rifalazil in Patients with Pulmonary Tuberculosis , 2001, Antimicrobial Agents and Chemotherapy.

[17]  Arkady Mustaev,et al.  Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase , 2001, Cell.

[18]  T. Wichelhaus,et al.  Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. , 2001, The Journal of antimicrobial chemotherapy.

[19]  T. Wichelhaus,et al.  Molecular Characterization of rpoBMutations Conferring Cross-Resistance to Rifamycins on Methicillin-Resistant Staphylococcus aureus , 1999, Antimicrobial Agents and Chemotherapy.

[20]  T. Quinn,et al.  Azithromycin in control of trachoma , 1999, The Lancet.

[21]  S. Kohno,et al.  Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. , 1998, The Journal of antimicrobial chemotherapy.

[22]  P. Gangadharam,et al.  Contribution of rpoB Mutations to Development of Rifamycin Cross-Resistance in Mycobacterium tuberculosis , 1998, Antimicrobial Agents and Chemotherapy.

[23]  K. Fujii,et al.  Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs , 1996, Antimicrobial agents and chemotherapy.

[24]  J. Musser,et al.  Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations , 1996, Antimicrobial agents and chemotherapy.

[25]  H. Tomioka,et al.  Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648 , 1995, Antimicrobial agents and chemotherapy.

[26]  W. Beatty,et al.  Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. , 1994, Microbiological reviews.

[27]  J. Grayston.  Chlamydia pneumoniae, strain TWAR pneumonia. , 1992, Annual review of medicine.